AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21334626 — intervention group
Group type: COMPARATOR
Intervention: Overweight children
Number of subjects: 27
Study 19724979 — intervention group
Group type: EXPERIMENTAL
Intervention: OXC/TIA
Number of subjects: 56
Study 19724979 — intervention group
Group type: COMPARATOR
Intervention: CLO
Number of subjects: 56
Study 17803010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 15
Study 17803010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15145924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Sil) 3 x 40 mg/day
Number of subjects: 12
Study 15145924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 12
Study 15145924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Sil)
Number of subjects: 12
Study 11759179 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 29
Study 11759179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9510340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 480
Study 9510340 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 480
Study 8062500 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (30 mg every 6 hours) with hydrochlorothiazide/amiloride (50 mg/5 mg daily)
Number of subjects: 0
Study 8062500 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (30 mg every 6 hours) with placebo
Number of subjects: 0
Study 2897763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketobemidone + A29 (Ketogan)
Number of subjects: 309
Study 2897763 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 309
Study 31944251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing Spondylitis Performed‐Based Improvement (ASPI)
Number of subjects: 58
Study 31944251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 58
Study 31944251 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 30562225 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthesia (LIA) with 150 ml of ropivacaine 0.2% at the end of surgery.
Number of subjects: 40
Study 30562225 — intervention group
Group type: COMPARATOR
Intervention: Single-shot sciatic nerve block with 20 ml of ropivacaine 0.75% and adductor canal block with catheter infusion of ropivacaine 0.2% at 6 ml/h for less than 4 days.
Number of subjects: 40
Study 27472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Badminton
Number of subjects: 36
Study 27472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 36
Study 27472020 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 25881510 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25
Number of subjects: 0
Study 25881510 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 24040301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 39
Study 24040301 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 39
Study 21415269 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 657
Study 21415269 — intervention group
Group type: COMPARATOR
Intervention: No Gemtuzumab ozogamicin (GO)
Number of subjects: 657
Study 21415269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin and autologous HCT in favorable-risk AML
Number of subjects: 657
Study 21415269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin and autologous HCT in intermediate-risk AML
Number of subjects: 657
Study 19171056 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual weaning (PSV manual group)
Number of subjects: 106
Study 19171056 — intervention group
Group type: COMPARATOR
Intervention: Automatic weaning (MRV automatic group)
Number of subjects: 106
Study 19171056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 17299489 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-60 g of retrograded resistant maltodextrins (RRM)
Number of subjects: 41
Study 17299489 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradually increasing doses of RRM over 21 days
Number of subjects: 41
Study 17299489 — intervention group
Group type: EXPERIMENTAL
Intervention: >60 g RRM
Number of subjects: 41
Study 14734593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (750 mg or 1000 mg, twice daily)
Number of subjects: 823
Study 14734593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823
Study 11890236 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic ureterolithotomy (RPUL)
Number of subjects: 55
Study 11890236 — intervention group
Group type: COMPARATOR
Intervention: Open ureterolithotomy
Number of subjects: 55
Study 9469533 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 0
Study 9469533 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 0
Study 7940682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP)
Number of subjects: 119
Study 7940682 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 119
Study 3369332 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session hypnosis
Number of subjects: 60
Study 3369332 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 60
Study 3369332 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study 31075858 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetitive Pavlovian-to-Instrumental Transfer (PIT) paradigm
Number of subjects: 51
Study 31075858 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-Factor Eating Questionnaire Disinhibition scale
Number of subjects: 51
Study 31075858 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Restraint scores
Number of subjects: 51
Study 28286115 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented renal clearance (ARC) patients receiving β-lactam therapy
Number of subjects: 254
Study 28286115 — intervention group
Group type: COMPARATOR
Intervention: Patients without augmented renal clearance (no ARC) receiving β-lactam therapy
Number of subjects: 254
Study 28286115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ARC and no ARC patients receiving β-lactam therapy
Number of subjects: 254
Study 25928649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 0
Study 23295775 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative group intervention (10 weekly group sessions and 2 booster meetings)
Number of subjects: 304
Study 23295775 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative group intervention
Number of subjects: 304
Study 23295775 — intervention group
Group type: COMPARATOR
Intervention: Control condition (pure GP training)
Number of subjects: 304
Study 21867621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) - CF + VDT protocol
Number of subjects: 180
Study 17420513 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐MCP (mitoxantrone, chlorambucil, prednisolone + rituximab)
Number of subjects: 201
Study 17420513 — intervention group
Group type: COMPARATOR
Intervention: MCP (mitoxantrone, chlorambucil, prednisolone)
Number of subjects: 201
Study 15891590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hologic experimental paediatric protocol for whole body
Number of subjects: 103
Study 15891590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hologic low-density protocol for lumbar spine
Number of subjects: 103
Study 15891590 — intervention group
Group type: COMPARATOR
Intervention: Standard adult protocol
Number of subjects: 103
Study 12173945 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g;pdd(‐1) of CLA with 3 g;pdd(‐1) of fatty acids for 28 days
Number of subjects: 23
Study 12173945 — intervention group
Group type: COMPARATOR
Intervention: 9 g;pdd(‐1) of an olive oil placebo for 28 days
Number of subjects: 23
Study 9880995 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized odds-rate class of regression models for time to event data
Number of subjects: 0
Study 8597965 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg.kg‐1
Number of subjects: 20
Study 8597965 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg.kg‐1
Number of subjects: 20
Study 8597965 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.6 mg.kg‐1
Number of subjects: 20
Study 8597965 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (control group)
Number of subjects: 20
Study 2483443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 13
Study 2483443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 13
Study 2483443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine
Number of subjects: 13
Study 2483443 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 13
Study 4820642 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and fresh frozen plasma
Number of subjects: 22
Study 4820642 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma alone
Number of subjects: 22
Study 30280513 — intervention group
Group type: EXPERIMENTAL
Intervention: PEACH™ intervention (6-month family-based weight management programme)
Number of subjects: 169
Study 27184784 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM intervention (Pharmacists and pharmacy technicians using novel tools for improving adherence and feedback)
Number of subjects: 576
Study 27184784 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM intervention
Number of subjects: 576
Study 25402666 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 72
Study 22985565 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg once a year)
Number of subjects: 48
Study 22985565 — intervention group
Group type: COMPARATOR
Intervention: Control group (Vitamin D3 and Caltrate daily for a year)
Number of subjects: 48
Study 20657535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF Afragil®
Number of subjects: 65
Study 20657535 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study 18570599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg once each morning
Number of subjects: 10
Study 18570599 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine 6 mg (2 mg in the morning and 4 mg after 12 h)
Number of subjects: 10
Study 15912655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1,000 mg/day)
Number of subjects: 41
Study 15912655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15912655 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 41
Study 15912655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 41
Study 12478147 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-dosing based on serum testosterone
Number of subjects: 22
Study 10718909 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.15 U/kg)
Number of subjects: 8
Study 10718909 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 8
Study 10718909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.0143 IU/kg)
Number of subjects: 8
Study 10718909 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone and vasopressin in combination
Number of subjects: 8
Study 10718909 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 8
Study 8794436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17 beta‐estradiol continuously
Number of subjects: 30
Study 8794436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta‐estradiol continuously
Number of subjects: 30
Study 8794436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg 17 beta‐estradiol alternating every 42 days
Number of subjects: 30
Study 8794436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen-progestogen phase
Number of subjects: 30
Study 1352247 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 2 mg b.d. p.o. for 10 days
Number of subjects: 16
Study 1352247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6466017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction (40 mEq of sodium daily)
Number of subjects: 0
Study 6466017 — intervention group
Group type: COMPARATOR
Intervention: Sodium supplementation to maintain baseline sodium intake (210 mEq/day)
Number of subjects: 0
Study 30623236 — intervention group
Group type: COMPARATOR
Intervention: IA-HA (2 ml/week, for 3 weeks)
Number of subjects: 120
Study 30623236 — intervention group
Group type: COMPARATOR
Intervention: IA-CS (1 ml)
Number of subjects: 120
Study 30623236 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-PRP (4 ml, 3 times, every 3 weeks)
Number of subjects: 120
Study 29224460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking chair therapy (vestibular stimulation)
Number of subjects: 0
Study 27132044 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30mg, oral)
Number of subjects: 0
Study 27132044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24566573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 48
Study 24566573 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB (length: 311 nm)
Number of subjects: 48
Study 21538084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexpulse intervention
Number of subjects: 0
Study 21538084 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 20719303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 39
Study 20719303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17614188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth mousse (CPP-ACP agent) applied on group A
Number of subjects: 40
Study 17614188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth mousse (CPP-ACP agent) applied on group C
Number of subjects: 40
Study 17614188 — intervention group
Group type: COMPARATOR
Intervention: No agent applied on group B
Number of subjects: 40
Study 17614188 — intervention group
Group type: COMPARATOR
Intervention: No agent applied on group D
Number of subjects: 40
Study 16261661 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral polyestradiol phosphate (PEP) therapy (240 mg/month)
Number of subjects: 444
Study 16261661 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy (OE)
Number of subjects: 444
Study 12016597 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Number of subjects: 30
Study 12016597 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Number of subjects: 30
Study 10511390 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion
Number of subjects: 11629
Study 10511390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 11629
Study 10511390 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, body mass index, alcohol consumption, and pulse rate
Number of subjects: 11629
Study 8821992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 micrograms of inhaled beclomethasone dipropionate (BDP) daily for at least 3 months
Number of subjects: 21
Study 8821992 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of oral prednisolone for 3 weeks
Number of subjects: 21
Study 8821992 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 21
Study 1833252 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial counseling
Number of subjects: 115
Study 1833252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial counseling)
Number of subjects: 115
Study 6289058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 50
Study 6289058 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg three times a day and 400 mg at night)
Number of subjects: 50
Study 6289058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ranitidine and cimetidine
Number of subjects: 50
Study 29644875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-200
Number of subjects: 311
Study 29644875 — intervention group
Group type: COMPARATOR
Intervention: PBS
Number of subjects: 311
Study 29181534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study 26437056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide 2 g/m2 + G-CSF (arm A)
Number of subjects: 69
Study 26437056 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone (arm B)
Number of subjects: 69
Study 23916416 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 120
Study 23916416 — intervention group
Group type: COMPARATOR
Intervention: Frequencies with icon arrays
Number of subjects: 120
Study 23916416 — intervention group
Group type: COMPARATOR
Intervention: Percentages
Number of subjects: 120
Study 23916416 — intervention group
Group type: COMPARATOR
Intervention: Frequencies
Number of subjects: 120
Study 21464679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week supply of nicotine patches
Number of subjects: 2806
Study 21464679 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week supply of nicotine patches
Number of subjects: 2806
Study 21464679 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week supply of nicotine patches
Number of subjects: 2806
Study 21464679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per attributable quit
Number of subjects: 2806
Study 17848939 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction (WR)
Number of subjects: 46
Study 17848939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 17252892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention (n = 15)
Number of subjects: 30
Study 17252892 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study 12606290 — intervention group
Group type: COMPARATOR
Intervention: Exposure to ethyl benzene (10 and 98 ppm) and 2-butanone (10 and 189 ppm) for 4 hours in experiment I.
Number of subjects: 24
Study 12606290 — intervention group
Group type: COMPARATOR
Intervention: Exposure to 2-propanol (35 and 190 ppm) and 1-octanol (0.1 and 6.4 ppm) for 4 hours in experiment II.
Number of subjects: 24
Study 12606290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both experiments involved exposure to solvents for 4 hours.
Number of subjects: 24
Study 10848721 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3% doxepin hydrochloride
Number of subjects: 200
Study 10848721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin
Number of subjects: 200
Study 10848721 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3.3% doxepin and 0.025% capsaicin
Number of subjects: 200
Study 10848721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9085951 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB) with 30 mL of 3% alkalinized chloroprocaine
Number of subjects: 68
Study 9085951 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with 65 mg of 5% hyperbaric lidocaine
Number of subjects: 68
Study 8285849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate; specific dosage and duration not mentioned
Number of subjects: 0
Study 3781705 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg three times daily for three weeks)
Number of subjects: 18
Study 3781705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30407291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bettercog
Number of subjects: 20
Study 30407291 — intervention group
Group type: COMPARATOR
Intervention: COMCOG
Number of subjects: 20
Study 26784137 — intervention group
Group type: COMPARATOR
Intervention: Palliative care for patients with COPD
Number of subjects: 0
Study 26784137 — intervention group
Group type: COMPARATOR
Intervention: Palliative care for patients with ILD
Number of subjects: 0
Study 26784137 — intervention group
Group type: COMPARATOR
Intervention: Palliative care for patients with COPD and ILD
Number of subjects: 0
Study 26784137 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care for patients with cancer
Number of subjects: 0
Study 24809884 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Cream (Eucerin Eczema Relief Body Crème) applied twice daily for 14 days, followed by a 5-day regression period.
Number of subjects: 0
Study 24809884 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant Therapy (Eucerin Eczema Relief Instant Therapy) for active atopic dermatitis lesions administered for 14 days.
Number of subjects: 0
Study 22317754 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based relapse prevention program (RP)
Number of subjects: 258
Study 22317754 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 258
Study 20300015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical blend (EXP; n = 12)
Number of subjects: 22
Study 20300015 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric equivalent (CON; n = 10)
Number of subjects: 22
Study 18724016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil Group (n=37)
Number of subjects: 73
Study 18724016 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=36)
Number of subjects: 73
Study 18259010 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed preeclampsia
Number of subjects: 822
Study 15462619 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatedly conflict with each other
Number of subjects: 0